Innate Pharma said its first-half 2026 developments included closing a strategic partnership with Sobi for lacutamab, completing dose-escalation enrollment for IPH4502, and completing enrollment in the PACIFIC-9 phase III study of monalizumab. Chief Executive Officer Jonathan Dickinson said the Sobi transaction became effective on closing and included a $75 million upfront payment, which combined with a €30 million equity financing is expected to extend the company's projected cash runway through the end of the first quarter of 2028. The Sobi agreement also carries up to $40 million in near-term Sézary syndrome milestones, up to an additional $465 million tied to development-rights options and future regulatory and commercial milestones, and tiered double-digit royalties on future net sales. Innate has initiated the TELLOMAK-3 confirmatory phase III trial of lacutamab in cutaneous T-cell lymphoma, with the first patient expected in the first quarter of 2027, and plans to seek accelerated approval in Sézary syndrome in the second half of 2027. The company expects key clinical updates in the second half of 2026, including a PACIFIC-9 phase III readout for monalizumab and initial phase I data for IPH4502, an antibody-drug conjugate that has shown preliminary responses in several heavily pretreated solid-tumor populations.
Innate PharmaClosed Sobi lacutamab deal ($75M upfront) plus €30M equity raise extends cash runway to Q1 2028.
Swedish Orphan Biovitrum ABSobi's lacutamab partnership became effective, with a $75M upfront payment plus up to $40M near-term and $465M later milestones and tiered royalties.
